Tag: stomach cancer

Oncotarget News

Figure 5: TAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling.

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

July 8, 2024

In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.”BUFFALO, NY- July 8, 2024 – A new research paper... read more

Figure 3: Cancer-specific survival curve based on the inflammation-based prognostic index. Abbreviation: ICPI: inflammation based prognostic index.

Oncotarget

Oncotarget | Novel Prognostic Index to Predict Survival Outcomes in Gastric Cancer Patients

February 14, 2023

In this study, the ICPI [inflammation-combined prognostic index] was devised as a novel predictive index of prognosis, and its usefulness was clarified.” BUFFALO, NY- February 14, 2023 – A new... read more